Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP vs XG in Advanced Esophageal Squamous Cell Carcinoma
NCT01474642Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Sep 2008
- Primary completion
- Sep 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Samsung Medical Center. Started Sep 2008; status: completed.
02
Drugs
capecitabine
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01474642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01474642.